Standard BioTools Inc
NASDAQ:LAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (3.6), the stock would be worth $0.79 (12% downside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4.1 | $0.9 |
0%
|
| 3-Year Average | 3.6 | $0.79 |
-12%
|
| 5-Year Average | 2.5 | $0.55 |
-39%
|
| Industry Average | 5.1 | $1.12 |
+24%
|
| Country Average | 2.4 | $0.54 |
-40%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$343.9m
|
/ |
Jan 2026
$85.3m
|
= |
|
|
$343.9m
|
/ |
Dec 2026
$82.3m
|
= |
|
|
$343.9m
|
/ |
Dec 2027
$84.5m
|
= |
|
|
$343.9m
|
/ |
Dec 2028
$88m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Standard BioTools Inc
NASDAQ:LAB
|
347.2m USD | 4.1 | -4.6 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
962.6B USD | 335.6 | 3 973.8 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
173.9B USD | 3.8 | 25.4 | |
| US |
|
Danaher Corp
NYSE:DHR
|
127.8B USD | 5.2 | 34.7 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 18.1 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
299.9B CNY | 6.6 | 15.7 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.9B CHF | 5.1 | -122 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 4.6 | 25.3 | |
| US |
|
Waters Corp
NYSE:WAT
|
29.4B USD | 9.3 | 45.8 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.8B USD | 1.7 | 20.5 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26B USD | 6.4 | 29.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
Standard BioTools Inc
Glance View
Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.
